LIB-01 will be the first choice of treatment of erectile dysfunction and premature ejaculation among the 500 million men who are affected. And thus, take a crucial part of the market for sexual dysfunctions.

Get to know the board


About Dicot

We address a problem that affects the quality of life for more than half of all men in the world over the age of 40. And it also affects the partner and the relationship to a high degree. There are also clear links to mental illness.

We feel strongly for those affected and we aim to develop a new modern potency drug to help these men and couples to regain a normal sex life.

Demand for medicines is increasing rapidly and there is a great need for new treatments in this area. If we can develop a new, well-functioning drug, it would make a huge difference.

Elin Trampe, CEO Dicot